Different opioids had different safety profiles when administered to older adults for noncancer pain, according to results from a new study published in the Archives of Internal Medicine.
Different opioids had different safety profiles when administered to older adults for noncancer pain, according to results from a new study published in the Archives of Internal Medicine.
"Almost no information exists about the comparative safety of opioids regarding serious adverse events, such as fractures, cardiovascular events, hospitalizations for gastrointestinal toxic effects, or mortality," noted researchers from Brigham and Women's Hospital in Boston, in their paper. They further stressed, "This vacuum of information presents a major problem for patients and providers."
To address this paucity of information, the researchers conducted an observational study using data from 2 US states that provided unrestricted coverage of opioids to Medicare beneficiaries through state-run pharmaceutical assistance programs. Researchers were able to identify new initiators of opioid therapy for noncancer pain, and then propensity-score match patients receiving codeine phosphate, hydrocodone bitartrate, oxycodone hydrochloride, propoxyphene hydrochloride, and tramadol hydrochloride in order to assure that the 6,275 patients in each of the 5 opioid groups had similar baseline characteristics.
According to Daniel H. Solomon, MD, MPH, lead author on this new paper, "This study's findings do not agree with a commonly held belief that all opioids are associated with similar risk." He stressed, "Our findings regarding cardiovascular risk were surprising and require validation in other data sets."
In an accompanying editorial, William C. Becker, MD, and Patrick G. O'Connor, MD, MPH, from the Yale University School of Medicine, New Haven, Conn., noted, "In contrast to the cardiovascular findings, elevated fracture risk with opioid use has solid biological plausibility through both of the mechanisms cited by the authors: increased fall risk and, although less relevant in this cohort of elderly initiates of opioid therapy, central effects on the hypothalamic-pituitary-adrenal axis that suppress androgen and estradiol production." Moreover, Drs Becker and O'Connor emphasized, "That the weaker opioids tramadol and propoxyphene had a decreased risk of fracture compared with the stronger opioids hydrocodone and oxycodone suggests a direct relationship between potency of the opioid and risk of falling and possibly decreased bone mass."
The study's researchers concluded their report by suggesting that the increased risk of various adverse events seen upon treating older adults for noncancer pain with opioids should be considered clinically relevant and should prompt caution and further study. However, they remarked, "We doubt that the comparative safety of multiple opioids will ever be adequately tested in a randomized controlled trial."
SOURCES
Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170(22):1979–1986.
Becker WC, O'Connor PG. The safety of opioid analgesics in the elderly: new data raise new concerns: comment on "The comparative safety of opioids for nonmalignant pain in older adults." Arch Intern Med. 2010;170(22):1986–1988.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.